COLO B Coloplast A/S Class B

Coloplast awarded Ostomy Products contract with Vizient

Coloplast awarded Ostomy Products contract with Vizient

Press release, 29 March, 2021

Coloplast, a global medical device company and market leader in intimate healthcare, has been awarded a contract for ostomy products with ., the largest healthcare performance improvement company in the US.

“I am excited about the agreement with Vizient and the potential it holds for our company, for Vizient members and for the many people living with an ostomy in the US. This agreement will strengthen our presence across hospitals and other healthcare organizations and enable us to provide our products and services to more and more users in the US,” says President & CEO of Coloplast, Kristian Villumsen.

The new agreement allows Vizient members access with contracted pricing to Coloplast’s full portfolio of ostomy products, including ostomy pouches and supporting products.

“We are delighted that Vizient has added us to their Ostomy Products portfolio. Vizient helps their members deliver high-value care to improve patient outcomes, and as a global market leader in intimate healthcare, we look forward to supporting that mission,” says Senior Vice President Manu Varma, Chronic Care North America, Coloplast.

The agreement is effective beginning July 1, 2021. As part of the contract, SenSura® Mio Baby & Kids, products developed by Coloplast for neonates, children and teenagers, will be included in Vizient’s Preferred Pediatric Program.

Vizient serves more than half of the healthcare organizations across the country – from large integrated delivery networks and academic medical centers to community hospitals, children’s hospitals and non-acute care providers.

About Coloplast ostomy products

Coloplast’s range of innovative ostomy products is designed to reduce leakage and maintain healthy skin. With the SenSura® Mio portfolio and BodyFit Technology, Coloplast has taken fit, flexibility, and comfort to a new level, creating a portfolio of innovative ostomy solutions that reduce the burden of leakage and enable users to live the life they want to lead.

In addition to product solutions, Coloplast has developed Coloplast® Care, the only manufacturer-provided patient support program with better patient outcomes supported by peer-reviewed data. Coloplast Care provides ostomy users access to product and lifestyle education and tools for self-assessment and individualized support from Care Advisors. Coloplast Care provides reliable information so ostomy users can better manage their care and experience a full life.

About Coloplast

Danish medical device company, Coloplast, develops products and services designed to make life easier for people with intimate health conditions. Coloplast listens to end-users to better understand their needs and responds by bringing the best ideas to market in the form of medical devices and service solutions.

Learn more on

Global press contact

Dennis Kaysen, Senior Director, Corporate Communications



Ellen Bjurgert, Vice President, Investor Relations



Attachment



EN
29/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Coloplast A/S Class B

 PRESS RELEASE

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 Sep...

Coloplast A/S - Invitation to Coloplast's Capital Markets Day on 2 September 2025 The event will take place on Tuesday, 2 September 2025 at Clarion Hotel (Copenhagen airport)Ellehammersvej 20, 2770 Kastrupfrom 10.30 - 17.00 CEST(Central European Summer Time) Coloplast invites institutional investors, equity analysts and media to attend our 2025 Capital Markets Day.The event will be held in person at Clarion Hotel in Copenhagen, Denmark, with the option to join virtually for the plenary session.The purpose of the event is to give institutional investors and financial analysts an introductio...

Coloplast AS: 1 director

A director at Coloplast AS bought 18,450 shares at 650.500DKK and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående p...

Coloplast A/S - Bestyrelsesmedlemmers, direktørers eller nærtstående personers handel med Coloplast-aktier Se venligst vedlagte pdf.   Vedhæftet fil

 PRESS RELEASE

Coloplast A/S - Trading in Coloplast shares by board members, executiv...

Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Please see enclosed pdf.   Attachment

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen

ResearchPool Subscriptions

Get the most out of your insights

Get in touch